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182 LETTERS TO THE EDITORThe two figures shown for the high dose study are dicult
to interpret and do not provide sucient evidence to
support the conclusion the two formulations have equiva-
lent tolerability.
In their discussion Milanowski and colleagues question
the design of clinical studies of other HFA-BDP prepara-
tions. There is currently only one HFA-BDP preparation
(Qvar, 3M Pharmaceuticals) licenced in the U.K. There are
many robustly designed studies that have been conducted
using this formulation in both symptomatic and well
controlled, steroid requiring and steroid naı¨ve patients,
for both short (6–12 week) and long term (12 months)
(1,2,3,4,5). There is also a well designed dose response study
which compares CFC-BDP and HFA-BDP in a direct mcg
for mcg comparison (6). All these studies show that patients
can be adequately controlled on around half the dose of
CFC-BDP without loss of asthma control. The comments
by Milanowski et al. on the risk of loss of asthma control in
well controlled patients and unwanted systemic eects when
switched to Qvar are thus incorrect and unwarranted.
In contrast to this, Milanowski correctly reports that
there is one study which indicates that the HFA-BDP
formulation from 3M Pharmaceuticals is equivalent to
CFC-BDP (7). This study was only designed to provide an
initial indication of absolute ecacy and was not ade-
quately powered to allow formal conclusions to be drawn
on the relative potency of Qvar compared with CFC-BDP.
Careful reading of the paper shows that the patients in this
study were well controlled, the average baseline FEV1 as a
percent of predicted being 805%, near their lung function
ceiling. For this group of patients it is likely that neither
formulation of beclomethasone would show a large increase
in pulmonary function but would just demonstrate that
control of asthma symptoms could be maintained. However
this highlights the point that interpretation of the outcome
of a single study in extending to a wider treatment
population should be viewed carefully until supported by
other robustly designed trials.
In conclusion, I believe that data presented by Mila-
nowski and colleagues should be viewed with extreme
caution. The data presented, both statistically and clini-
cally, do not support the claims made of clinical equiva-
lence. More rigorously designed studies on this formulation
should be reported before a conclusion of clinical equiva-
lence can be made.
J. G. AYRES
Department of Respiratory Medicine,
Birmingham Heartlands Hospital, U.K.
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Inhaled beclomethasone (BDP) with
non-CFC propellant (HFA 134a) is
equivalent to BDP-CFC for the
treatment of asthma (Respir Med 1999;
93: 245±251)Milanowski et al. (1) imply that CFC and HFA-propellant
formulated beclomethasone dipropionate (BDP) were
equipotent in their eects on lung function and asthma
symptoms in subjects with sub-optimally controlled asth-
ma. What they have in fact shown is that low and high
doses of both formulations of BDP produced similar
changes in spirometric values and symptoms suggesting
that the response had reached a plateau with the lower
dose. A more clear cut dose–response relationship may
have been seen with markers of the systemic eects of
inhaled BDP and it is unfortunate that the data on 0900 h
cortisol concentrations before and after treatment was not
presented more fully. The figure illustrating abnormal
cortisol concentrations during the high dose study shows
that 13 subjects with normal cortisol concentrations at
baseline developed low concentrations during treatment
with BDP-HFA compared to two subjects with BDP-CFC.
This suggests than BDP-HFA is more potent and/or more
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changes from baseline in 0900 h cortisol during treatment
significantly dierent? Without seeing this data most
clinicians would be unhappy to accept the authors assertion
that the dierent formulations of BDP are equivalent.
I. D. PAVORD
Consultant Physician, Glen®eld Hospital,
Groby Road, Leicester, UK LE3 9QP
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Response to letters of Professor Ayres
and Dr Pavord re: paper by
Milanowski et al. (Respir Med 1999; 93:
245±251)We thank Professor Ayres and Dr Pavord for their letters
and would like to point out that the results in our paper
have since been borne out in further large studies in other
asthmatic populations, which will be published in due
course (1). With regard to what constitutes therapeutic
equivalence between two asthma preparations, there is no
consensus on this, nor on what would be likely to represent
a clinically significant dierence. Our choice of a 02 l
dierence in mean FEV1 was considered unlikely to
represent a meaningful dierence in therapeutic practice
between BDP-HFA and BDP-CFC preparations, but in
practice this threshold value could well be greater. The
cumulative evidence from the studies we have performed is
that any clinically significant dierence in asthma control
between treatments would not be missed. It is important
also to reiterate that the primary purpose of the high dose
study was to assess comparable safety and tolerability of
the BDP-HFA preparation in patients switched from BDP-
CFC. It is acknowledged that it is extremely dicult to
detect changes in lung function near the top of the dose–
response curve for inhaled corticosteroids.
On the question of the choice of a four times daily
dosage. In these studies, this was a recommendation in the
data sheet for BDP at the time and indeed currently.
Although twice daily regimens are now more usually
adopted, there is no suggestion of dierent compliance
with either BDP-CFC or BDP-HFA in later studies.
In answer to Professor Ayres’ concern, the drawbacks to
using morning plasma cortisol are also acknowledged, butthis is still a commonly used parameter in clinical trials (2),
along with urinary 24 h cortisol excretion to assess HPA
axis function. It is also inevitable that some patients being
treated with high dose (2000 mcg daily) inhaled corticos-
teroids will exhibit low plasma cortisol values at some stage.
This was indeed the case in our high dose study, but the
important point was that the proportions of such patients
were not significantly dierent between treatments (31% vs.
36%) and this was clearly stated in our paper. More
importantly, subsequent work has shown no dierences in
HPA axis function in asthmatic patients between BDP-
HFA and BDP-CFC using 24 h urinary cortisol and
Synacthen stimulation tests.
With reference to other peer-reviewed published BDP-
HFA studies with QvarTM (3M Pharmaceuticals, U.K.)
cited by Professor Ayres, we are unaware of any of these
comparing both half and full dose BDP-HFA with full dose
BDP-CFC in large patient populations in a therapeutic
setting. We are also unaware of any data showing that a
50% reduction in dose of BDP-HFA compared with BDP-
CFC results in a halving of the incidence of either side
eects or cortisol suppression, surely the real purpose of
adopting this strategy. Furthermore, it is not valid just to
dismiss the earlier paper by Dahl et al., 1997, as Professor
Ayres has done. This paper showed a 1:1 dose equivalence
between BDP-HFA and BDP-CFC. The objectives of this
study were clearly set out in the paper which was properly
designed and powered to achieve its aims.
We agree with both Professor Ayres and Dr Pavord that
further studies are useful to confirm the results here and
indeed these have already taken place, as stated above.
Based on all currently available evidence we maintain that
the BDP-HFA and BDP-CFC equivalence is close to 1:1.
For clinical purposes, it is more pragmatic to switch
patients between BDP-CFC and BDP-HFA preparations at
the same dose to avoid confusion and then subsequently to
titrate the dose individually, as necessary.
J. MILANOWSKI AND V. L. PERRIN
Medical Department, Norton Healthcare Ltd,
London, U.K.
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